See more : NAVA HEALTH MD, LLC (NAVA) Income Statement Analysis – Financial Results
Complete financial analysis of Silverback Therapeutics, Inc. (SBTX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Silverback Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Xi’an International Medical Investment Company Limited (000516.SZ) Income Statement Analysis – Financial Results
- Zymergen Inc. (ZY) Income Statement Analysis – Financial Results
- ID Holdings Corporation (4709.T) Income Statement Analysis – Financial Results
- Duckyang Ind. Co., Ltd. (024900.KS) Income Statement Analysis – Financial Results
- Aferian Plc (AOECF) Income Statement Analysis – Financial Results
Silverback Therapeutics, Inc. (SBTX)
About Silverback Therapeutics, Inc.
Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 18.38M | 61.50M | 24.58M | 21.51M | 14.80M |
| General & Administrative | 18.46M | 28.08M | 8.34M | 2.56M | 3.52M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 18.46M | 28.08M | 8.34M | 2.56M | 3.52M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 36.83M | 89.58M | 32.92M | 24.07M | 18.32M |
| Cost & Expenses | 36.83M | 89.58M | 32.92M | 24.07M | 18.32M |
| Interest Income | 0.00 | 0.00 | -29.00K | 100.00K | 43.00K |
| Interest Expense | -834.00K | 106.00K | -29.00K | 0.00 | 0.00 |
| Depreciation & Amortization | 319.00K | 783.00K | 637.00K | 544.00K | 480.00K |
| EBITDA | -35.52M | -88.59M | -32.31M | -23.42M | -17.10M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -35.52M | -89.37M | -32.92M | -24.07M | -18.32M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 834.00K | 106.00K | -29.00K | 100.00K | 741.00K |
| Income Before Tax | -34.68M | -89.48M | -32.95M | -23.97M | -17.58M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -834.00K | 106.00K | -29.00K | 100.00K | 741.00K |
| Net Income | -33.85M | -89.58M | -32.95M | -23.97M | -17.58M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.85 | -30.81 | -11.33 | -4.90 | -3.59 |
| EPS Diluted | -0.85 | -30.81 | -11.33 | -4.90 | -3.59 |
| Weighted Avg Shares Out | 39.96M | 2.91M | 2.91M | 4.89M | 4.89M |
| Weighted Avg Shares Out (Dil) | 39.96M | 2.91M | 2.91M | 4.89M | 4.89M |
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Silverback Therapeutics, Inc. - SBTX
New York, New York--(Newsfile Corp. - September 21, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Silverback Therapeutics, Inc. ("Silverback" or the "Company") (NASDAQ: SBTX). Such investors are advised to contact Robert S. Willoughby at [email protected]...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Silverback Therapeutics, Inc. - SBTX
NEW YORK, Sept. 19, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Silverback Therapeutics, Inc. ("Silverback" or the "Company") (NASDAQ: SBTX).
Silverback Therapeutics Presents Initial Safety Data From Solid Tumor Combo Therapy Trial
Silverback Therapeutics Inc (NASDAQ: SBTX) has presented interim data from a Phase 1/1b study of SBT6050 as a monotherapy and in combination with Merck & Co Inc's (NYSE: MRK) Keytruda (pembrolizumab). Data were shared at the 2021 European Society for Medical Oncology Congress (ESMO21).
Silverback Therapeutics Presents Interim Clinical Results from the Ongoing Phase 1/1b Study of SBT6050 Alone or In Combination with Pembrolizumab in Patients with Advanced or Metastatic HER2-Expressing Solid Tumors
SEATTLE--(BUSINESS WIRE)--Silverback Therapeutics, Inc. (Nasdaq: SBTX) (“Silverback”), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases, today presented interim clinical...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Silverback Therapeutics, Inc. - SBTX
NEW YORK, Sept. 14, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Silverback Therapeutics, Inc. ("Silverback" or the "Company") (NASDAQ: SBTX).
Why Are Silverback Therapeutics Shares Falling On Monday?
Silverback Therapeutics Inc (NASDAQ: SBTX) stock dropped to the lowest level since its IPO in December 2020 in reaction to interim data from SBT6050 Phase 1/1b trial for solid tumors. The trial in advanced or metastatic HER2-expressing or amplified solid cancer was designed...
Silverback Therapeutics to Present Data from its Phase 1/1b Clinical Trial of SBT6050 at the European Society for Medical Oncology (ESMO) 2021 Virtual Congress
SEATTLE--(BUSINESS WIRE)--Silverback Therapeutics, Inc. (Nasdaq: SBTX) (“Silverback”), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases, today announced that interim...
Silverback Therapeutics to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference
SEATTLE--(BUSINESS WIRE)--Silverback Therapeutics, Inc. (Nasdaq: SBTX) (“Silverback”), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases, today announced that the...
Silverback Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update
SEATTLE--(BUSINESS WIRE)--Silverback Therapeutics, Inc. (Nasdaq: SBTX) (“Silverback”), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases, today reported financial results...
Silverback Therapeutics Announces the Appointment of Dr. Maria Koehler to its Board of Directors
SEATTLE--(BUSINESS WIRE)--Silverback Therapeutics, Inc. (Nasdaq: SBTX) (“Silverback”), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases, today announced the appointment...
Source: https://incomestatements.info
Category: Stock Reports